Related Experiment Video
Updated: Jun 6, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
[Effect of silencing connective tissue growth factor on the liver fibrosis in rats]
Guang-ming Li1, Ding-guo Li, Jian-gao Fan
1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China. ligm68@126.com
Objective:
To investigate the anti-fibrogenesis property of intraportal vein small interfering RNA (siRNA) injection targeting connective tissue growth factor (CTGF) in a rat model of liver fibrosis induced by carbon tetrachloride (CCl4) and its effect on hepatic stellate cell (HSC) activation.
Methods:
24 male rats were randomly divided into four group. rats received CCl4 by subcutaneous injections every three days for 6 consecutive weeks, and meantime they also obtained either siRNA targeting CTGF (as CTGF siRNA group), saline (as model group) or a control siRNA (as control siRNA group) by intraportal vein injection to rats liver at the same approach. Other rats received saline intraportal vein injection for 6 weeks (as normal control group). The expressions of CTGF and a-SMA protein were detected by Western blot. Hepatic histology was evaluated by HE staining and Sirius red staining. The collagen staining areas were measured quantitatively using a computer-aided manipulator with slight modifications. The number of active HSC were evaluated by immunohistochemistry.
Results:
Six weeks after CCl4 injection, prominent upregulations were observed in the expressions of CTGF and a-SMA protein in saline or control siRNA-treated rats livers. In rats with CTGF siRNA treatment, the protein expressions of CTGF and a-SMA in liver decreased by 95%+/-2% and 86%+/-11% (F=21.234 and 12.473, P<0.01) respectively, the number of active HSC in liver decreased by 76%+/-9% (F=9.179, P<0.01) as compared to the model group. The attenuation of liver fibrosis was also observed in rats with CTGF siRNA treatment.
Conclusion:
Intraportal vein siRNA injection targeting CTGF could significantly inhibit CTGF gene expression in rats, thereby attenuate liver fibrosis by decreasing the number of active HSCs.
Insights
Small interfering RNA (siRNA) targeting connective tissue growth factor (CTGF) effectively reduced liver fibrosis in rats. This approach significantly decreased CTGF and alpha-smooth muscle actin (a-SMA) protein levels and inhibited hepatic stellate cell activation.
Area of Science:
- Hepatology
- Molecular Biology
- RNA Interference Therapeutics
Background:
- Liver fibrosis is a significant health concern characterized by excessive extracellular matrix deposition.
- Connective tissue growth factor (CTGF) plays a crucial role in the pathogenesis of liver fibrosis.
- Hepatic stellate cell (HSC) activation is a key event in liver fibrogenesis.
Purpose of the Study:
- To evaluate the efficacy of intraportal vein small interfering RNA (siRNA) targeting CTGF in a rat model of liver fibrosis.
- To assess the impact of CTGF-targeting siRNA on HSC activation and fibrotic markers.
Main Methods:
- Liver fibrosis was induced in male rats using carbon tetrachloride (CCl4) injections over six weeks.
- Rats received intraportal vein injections of CTGF siRNA, control siRNA, or saline.
- Protein expression of CTGF and alpha-smooth muscle actin (a-SMA) was measured by Western blot.
- Histological analysis using HE and Sirius red staining assessed liver fibrosis and collagen deposition.
- Immunohistochemistry evaluated the number of active HSCs.
Main Results:
- CCl4 induction led to significant upregulation of CTGF and a-SMA in control groups.
- CTGF siRNA treatment markedly reduced CTGF and a-SMA protein levels by 95% and 86%, respectively.
- A significant decrease (76%) in active HSCs was observed in the CTGF siRNA group.
- Attenuation of liver fibrosis was evident in rats treated with CTGF siRNA.
Conclusions:
- Intraportal vein siRNA delivery targeting CTGF effectively inhibits CTGF gene expression in the liver.
- This targeted inhibition significantly attenuates liver fibrosis by reducing HSC activation.
- CTGF-targeting siRNA represents a promising therapeutic strategy for liver fibrosis.
Related Concept Videos
Cirrhosis II: Pathophysiology
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
